Insider Buying: Organogenesis Holdings Inc (NASDAQ:ORGO) Major Shareholder Purchases $21,618.00 in Stock

Share on StockTwits

Organogenesis Holdings Inc (NASDAQ:ORGO) major shareholder Michael W. Katz acquired 3,603 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were bought at an average cost of $6.00 per share, with a total value of $21,618.00. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Organogenesis stock opened at $5.85 on Friday. Organogenesis Holdings Inc has a 12 month low of $3.56 and a 12 month high of $310.90. The company has a current ratio of 1.51, a quick ratio of 1.14 and a debt-to-equity ratio of 3.78. The firm has a 50 day moving average price of $4.70.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. The firm had revenue of $64.95 million during the quarter, compared to analysts’ expectations of $61.00 million. On average, analysts predict that Organogenesis Holdings Inc will post -0.5 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC purchased a new position in Organogenesis in the second quarter valued at approximately $200,000. Bank of New York Mellon Corp purchased a new position in Organogenesis in the second quarter valued at approximately $210,000. Northern Trust Corp lifted its stake in Organogenesis by 134.3% in the second quarter. Northern Trust Corp now owns 41,066 shares of the company’s stock valued at $312,000 after purchasing an additional 23,540 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Organogenesis by 36.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 86,495 shares of the company’s stock valued at $658,000 after purchasing an additional 23,180 shares during the last quarter. Finally, Moors & Cabot Inc. purchased a new position in Organogenesis in the second quarter valued at approximately $694,000. Institutional investors and hedge funds own 1.68% of the company’s stock.

A number of analysts have commented on the company. Credit Suisse Group assumed coverage on Organogenesis in a report on Monday, August 26th. They set an “outperform” rating for the company. Zacks Investment Research lowered Organogenesis from a “hold” rating to a “sell” rating in a report on Friday. Finally, BTIG Research set a $12.00 price objective on Organogenesis and gave the stock a “buy” rating in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. Organogenesis currently has an average rating of “Buy” and an average price target of $10.80.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.

See Also: What is a trade deficit?

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.